Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Drug development

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Despite the increasing approval of antiamyloid antibodies for Alzheimer disease (AD), their clinical relevance and risk-benefit profile remain uncertain. The heterogeneity of AD and the limited availability of long-term clinical data make it difficult to establish a clear rationale for selecting one treatment over another. Objective The aim of this work was to assess and compare the efficacy and safety of antiamyloid antibodies through an interactive online meta-analytic approach by performing conventional pair-wise meta-analyses and frequentist and Bayesian network meta-analyses of phase II and III clinical trial results.

What this study adds

Evidence grade: High

This is a pooled review of 21,236 participants. This meta-analysis of phase II and III trials assessed the efficacy and safety of antiamyloid antibodies, but notes that limited long-term clinical data make it hard to establish a clear rationale for choosing one treatment over another. It does not report a definitive clinical benefit.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jeremic, D., Navarro-Lopez, J. D., & Jimenez-Diaz, L. (2025). Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application. Journal of medical Internet research. https://doi.org/10.2196/68454

Vancouver

Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L. Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application. Journal of medical Internet research. 2025. doi:10.2196/68454. PMID: 40194268.

BibTeX

@article{jeremic2025-40194268,
  author  = {Jeremic, D. and Navarro-Lopez, J. D. and Jimenez-Diaz, L.},
  title   = {{Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application}},
  journal = {Journal of medical Internet research},
  year    = {2025},
  doi     = {10.2196/68454},
  pmid    = {40194268},
  url     = {https://doi.org/10.2196/68454}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This meta-analysis of phase II and III trials assessed the efficacy and safety of antiamyloid antibodies, but notes that limited long-term clinical data make it hard to establish a clear rationale for choosing one treatment over another. It does not report a definitive clinical benefit.

Study details

How this study scored 62/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 62 of 100.62 of 100 points earned38 not earned

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of medical Internet research)
Journal's citation record 3 / 4 Journal of Medical Internet Research: journal h-index 286 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 21,236 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.3 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Lydia Jiménez‐Díaz: h-index 22 (OpenAlex, whole career)
Institution's track record 0 / 3 University of Castilla-La Mancha: institution h-index 351 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40194268)
Free to read 2 / 2 Free to read
Total 62 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Drug development from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →